A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19

Biological and Pharmaceutical Bulletin

Volumn 22, Issue 1, 1999, Pages 77-79

  Itoh, Kunihiko ^a   Inoue, Kazuyuki ^a   Yanagiwara, Seiko ^b   Kyoya, Hiroyuki ^a   Suzuki, Toshio ^a  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b AKITA RED CROSS HOSPITAL   (Japan)

Author keywords

CYP2C19; Genotyping; PCR restriction fragment length polymorphism (RFLP)

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 ISOENZYME; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME POLYMORPHISM; GENE MUTATION; GENOTYPE; HUMAN; JAPAN; NORMAL HUMAN; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 0032995228     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.22.77     Document Type: Article

References (16)

1. Kupfer A., Preisig R., Eur. J. Clin. Pharmacol., 26, 753-759 (1984).
2. Wedlund P J., Aslanian W. S., McAllister C. B., Wilkinson G. R., Branch R. A., Clin. Pharmacol. Ther., 36, 773-780 (1984).
3. Wilkinson G. R., Guengerich F. P., Branch R. A., Pharmacol. Therapeut., 43, 53-76 (1989).
4. Ward S. A., Goto F., Nakamura K., Jacqz E., Wilkinson G. R., Branch R. A. Clin. Pharmacol. Ther., 42, 96-99 (1987).
5. Inaba T., Jurima M., Kalow W. F., Am. J. Hum. Genet., 38, 768-772 (1986).
6. Nakamura K., Goto F., Ray W. A., McAllister C. B., Jacqz E., Wilkinson G. R., Branch R. A., Clin. Pharmacol. Ther., 38, 402-408 (1985).
7. Goldstein J. A., Faletto M. B., Romkes-Sparks M., Sullivan T., Kitareewan S., Raucy J. L., Lasker J. M., Ghanayem B. I., Biochemistry, 33, 1743-1752 (1994).
8. Wrighton S. A., Stevens J. C., Becker G. W., Van den Branden M., Arch. Biochem. Biophys., 306, 240-245 (1993).
9. de Morais S. M. F., Wilkinson G. R., Blaisdell J., Nakamura K., Meyer U. A., Goldstein J. A., J. Biol. Chem., 269, 15419-15422 (1994).
10. de Morais S. M. F., Wilkinson G. R., Blaisdell J., Meyer U. A., Nakamura K., Goldstein J. A., Mol. Pharmacol., 46, 594-598 (1994).
11. Adedoyin A., Prakash C., O'Shea D., Blair I. A., Wilkinson G. R., Pharmacogenetics, 4, 27-38 (1994).
12. Kupfer A., Branch R. A., Clin. Pharmacol. Ther., 38, 414-418 (1985).
13. Ieiri I., Kubota T., Urae A., Kimura M., Wada Y., Mayama K., Yoshioka S., Irie S., Amamoto T., Nakamura K., Nakano S., Higuchi S., Clin. Pharmacol. Ther., 59, 647-653 (1996).
14. Katsuki H., Nakamura C., Arimori K., Fujiyama S., Nakano M., Eur. J. Clin. Pharmacol., 52, 391-396 (1997).
15. Ward S. A., Helsby N. A., Skejlbo E., Brosen K., Gram L. F., Breckenridge A. M., Brit. J. Clin. Pharmacol., 31, 689-692 (1991).
16. Sindrup S. H., Brosen K., Hansen M. G. J., Aaes-Jorgensen T., Overo K. F., Gram L. F., Ther. Drug Monit., 13, 11-17 (1993).